# Lexicon Pharmaceuticals Inc. (LXRX) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $1.46, market value $650 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Lexicon Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 15.7×**. Each dollar of revenue is priced at 15.7×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 3.7×**. The shares trade at 3.7× book value; book value is a meaningful part of the valuation.

## Profitability
- **Operating margin: -131.4%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -101.1%**. The company reported a net loss over the last twelve months.
- **Return on equity: -46.8%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -33.8%**. Return on all capital, debt included, is -33.8%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -33.0%**. Each dollar of assets produces -33.0% of profit.

## Growth
- **Revenue growth (1 yr): 729.9%** (5-yr 16.3%/yr). Revenue grew 729.9% over the last year, against 16.3% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 77.8%**. Earnings per share rose 77.8%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.50**. Debt is 0.50 times equity, moderate leverage.
- **Net debt / EBITDA: net cash**. Lexicon Pharmaceuticals Inc. holds more cash than debt.
- **Current ratio: 4.88** (quick 4.88). Current assets cover the next year's liabilities 4.88 times.
- **Altman Z-score: 5.77**. A Z-score of 5.77 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Lexicon Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (6 analysts). 6 analysts cover Lexicon Pharmaceuticals Inc.; the consensus is buy, with an average price target of $4.46 (+206% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 4.3%** (YTD 25.2%, 3-mo -38.2%). The shares are up 4.3% over twelve months including dividends.
- **From 52-week high: -45.5%** (32.7% above the low). Trading 46% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 31**. An RSI of 31 is neutral.
- **Beta (1 yr): 1.52** (volatility 74%). Beta of 1.52 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=LXRX · Page: https://foliofundamentals.com/stocks/lxrx

Not investment advice.